EMC Capital Management Takes $75,000 Position in Integra LifeSciences Holdings Corporation $IART

EMC Capital Management bought a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,093 shares of the life sciences company’s stock, valued at approximately $75,000.

A number of other large investors also recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its position in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after acquiring an additional 2,108 shares during the period. AlphaQuest LLC acquired a new stake in Integra LifeSciences in the second quarter valued at approximately $73,000. CWM LLC increased its position in shares of Integra LifeSciences by 32.6% in the second quarter. CWM LLC now owns 8,834 shares of the life sciences company’s stock valued at $108,000 after buying an additional 2,170 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Integra LifeSciences by 6,017.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock worth $124,000 after buying an additional 9,929 shares during the period. Finally, Compass Financial Group INC SD purchased a new position in shares of Integra LifeSciences during the 2nd quarter valued at approximately $172,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeffrey A. Graves acquired 9,000 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were purchased at an average cost of $11.35 per share, for a total transaction of $102,150.00. Following the acquisition, the director owned 41,086 shares in the company, valued at $466,326.10. The trade was a 28.05% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.54% of the company’s stock.

Integra LifeSciences Stock Down 2.4%

Shares of NASDAQ IART opened at $11.15 on Thursday. The company has a market capitalization of $868.50 million, a P/E ratio of -1.71 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The company has a 50 day simple moving average of $13.80 and a 200-day simple moving average of $13.40. Integra LifeSciences Holdings Corporation has a 1 year low of $10.87 and a 1 year high of $27.13.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.11. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company had revenue of $402.06 million during the quarter, compared to analysts’ expectations of $414.31 million. During the same quarter last year, the firm earned $0.41 earnings per share. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. On average, equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Truist Financial restated a “hold” rating and set a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. JPMorgan Chase & Co. increased their target price on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Thursday, November 13th. Finally, Citigroup dropped their target price on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $15.83.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.